Regulation of ATM and ATR by SMARCAL1 and BRG1

Area of Science:

• Cellular biology
• Molecular genetics
• Biochemistry

Background:

• The G2/M cell cycle checkpoint prevents entry into mitosis until DNA damage is repaired.
• ATM (Ataxia-Telangiectasia Mutated) and ATR (Ataxia-Telangiectasia and Rad3-Related) are key kinases activated by DNA damage.
• Post-translational modifications regulate ATM and ATR activity.

Purpose of the Study:

• To investigate the transcriptional co-regulation of ATM and ATR by SMARCAL1 and BRG1.
• To elucidate the role of SMARCAL1 and BRG1 in the DNA damage response pathway.
• To understand the implications of SMARCAL1 and BRG1 mutations in human diseases.

Main Methods:

• Chromatin immunoprecipitation assays to assess protein localization.
• Western blotting and quantitative PCR to measure gene and protein expression levels.
• Cellular assays to evaluate G2/M checkpoint integrity and mitotic progression.

Main Results:

• SMARCAL1 and BRG1, ATP-dependent chromatin remodelers, co-localize at ATM and ATR promoters.
• Downregulation of SMARCAL1 or BRG1 leads to decreased ATM/ATR expression and G2/M checkpoint override.
• Doxorubicin treatment upregulates SMARCAL1 and BRG1, which subsequently enhance ATM/ATR expression.
• Phospho-ATM feedback regulates SMARCAL1, BRG1, ATM, and ATR promoters upon DNA damage.
• Mutations in SMARCAL1 (Schimke Immuno-Osseous Dysplasia) or BRG1 (Coffin-Siris Syndrome) impair ATM/ATR regulation.

Conclusions:

• SMARCAL1 and BRG1 are essential transcriptional co-regulators of ATM and ATR in response to DNA damage.
• This intricate regulatory mechanism ensures proper DNA damage response and cell cycle control in mammalian cells.
• Dysfunctional SMARCAL1 or BRG1 underlies genetic disorders characterized by DNA repair deficiencies.